Blood donations, iron stores, and risk of Parkinson's disease

Movement Disorders

Volumn 21, Issue 6, 2006, Pages 835-838

  Logroscino, Giancarlo ^a   Chen, Honglei ^b   Wing, Al ^a   Ascherio, Alberto ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Blood donation; Iron; Parkinson's disease; Risk cohort studies

Indexed keywords

FERRITIN; IRON;

ADULT; AGED; ARTICLE; BLOOD DONOR; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FOLLOW UP; HEALTH PRACTITIONER; HUMAN; HYPOTHESIS; IRON OVERLOAD; IRON STORAGE; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; SAMPLE SIZE; UNITED STATES;

ADULT; AGED; BLOOD DONORS; HUMANS; IRON; IRON OVERLOAD; MALE; MIDDLE AGED; PARKINSON DISEASE; PHYSICIANS; QUESTIONNAIRES; RISK; RISK FACTORS; UNITED STATES;

EID: 33745809508     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20826     Document Type: Article

References (20)

1. Dexter DT, Wells FR, Lees AL et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-1836.
2. Sofic E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in post mortern substantia nigra of parkinsonian brain. J Neural Transm 1988;74:199-205.
3. Ostrerova-Golts N, Petrucelli L, Hardy J, et al. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 2000;20:6048-6054.
4. Faucheux BA, Nillesse N, Damier P, et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci USA 1995;92:9603-9607.
5. Logroscino G, Marder K, Graziano J, et al. Altered systemic iron metabolism in Parkinson's disease. Neurology 1997;49:714-717.
6. Kaur D, Yantiri F, Rajagopalan S, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003;37:899-909.
7. Finch CA, Cook JD, Labbe RF, Culala M. Effect of blood donation on iron stores as evaluated by serum ferritin. Blood 1977;50:441-447.
8. Ascherio A, Rimm EB, Giovannucci E, et al. Blood donations and risk of coronary heart disease in men. Circulation 2001;103:52-57.
9. Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50:56-63.
10. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
11. Salonen JT, Tuomainen TP, Salonen R, et al. Donation of blood is associated with reduced risk of myocardial infarction: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Epidemiol 1998;148:445-451.
12. Octave J, Shneider Y, Truet A, et al. Iron uptake and utilization by mammalian cel: I, cellular uptake of transferring and iron. Trends Biochem Sci 1983;8:217-221.
13. Connor JR, Snyder BS, Arosio P, et al. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem 1995;65:717-724.
14. Galazka-Friedman J, Bauminger ER, Koziorowski D, Friedman A. Mossbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra. Biochim Biophys Acta 2004;1688:130-136.
15. Forte G, Bocca B, Senofonte O, et al. Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson's disease. J Neural Transm 2004; 111: 1031-1040.
16. Levenson CW, Cutler RG, Ladenheim B, et al. Role of dietary iron restriction in a mouse model of Parkinson's disease. Exp Neurol 2004;190:506-514.
17. Chen H, Zhang SM, Hernan MA, et al. Weight loss in Parkinson's disease. Ann Neurol 2003;53:676-679.
18. Cole GM. Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases? Neuron, 2003;37:889-890.
19. Gassen M, Youdim MB. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol Toxicol 1997;80:159-166.
20. Kaur D, Andersen J. Does cellular iron dysregulation play a causative role in Parkinson's disease? Ageing Res Rev 2004;3: 327-343.